“This notable investment in a homegrown company demonstrates the interconnectivity of our regional life sciences community and our skilled workforce infrastructure to support long-term company growth and high-paying jobs,” says Nancy Johnston, executive director for North Carolina Biotechnology Center’s Piedmont Triad Office. Here’s a detailed look at ProKidney and its investment decision.
Read More
A company developing treatments for kidney disease will invest $485 million and create some 330 jobs under an agreement approved Tuesday by the North Carolina Department of Commerce’s Economic Investment Committee.
Read More
Biomedical engineers at Duke University have developed a method to study how key cells in the kidneys become injured and deformed. The new model has revealed a significant mechanism behind severe kidney disease and pointed toward early disease biomarkers and potential therapeutic interventions.
Read More
ProKidney, an emerging entrepreneurial life science company targeting kidney disease, is planning to go public through a merger with a California firm and will become a company estimated to be valued at more than $2.6 billion with $825 million in cash.
Read More
